These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1002 related articles for article (PubMed ID: 15630677)

  • 1. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
    Harenberg J
    Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The United States Food and Drugs Administration approves a generic enoxaparin.
    Ofosu FA
    Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the available low-molecular-weight heparin preparations the same?
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
    Ofosu FA
    Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of generic low molecular weight heparins: a perspective.
    Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM; Jackson CM; Kessler CM
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparins: are they different?
    Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM
    Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
    Harenberg J
    Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of low molecular weight heparins in animal models.
    Fareed J; Fu K; Yang LH; Hoppensteadt DA
    Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.